SCHEMBL11944323

SCHEMBL11944323

CCCS(=O)(=O)N1CCN(c2cnn(C3CCCC3)c(=O)c2OC2CCCC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.42
▸ GLA P06280 1/20 0.42
▸ MAPT P10636 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ CNR2 P34972 1/20 0.38
▸ GPR119 Q8TDV5 5/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ GAA P10253 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ NAMPT P43490 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944157 0.99 KDM4E (0.42) KDM4EGLAMAPTHSD17B10CNR2
SCHEMBL11944319 0.98 KDM4E (0.41) KDM4EGLAMAPTHSD17B10CNR2
SCHEMBL11944372 0.91 KDM4E (0.39) KDM4EGLAMAPTHSD17B10CNR2
SCHEMBL11944199 0.87 ALDH1A1 (0.44) MAPTHSD17B10CNR2PKMKMT2A
SCHEMBL11944164 0.87 KDM4E (0.39) KDM4EGLAMAPTHSD17B10CNR2
SCHEMBL11944264 0.86 ALDH1A1 (0.43) CNR2KMT2AALDH1A1CCNE2CCNE1
SCHEMBL11944212 0.85 ALDH1A1 (0.43) CNR2KMT2AALDH1A1CCNE2CCNE1
SCHEMBL11944293 0.84 MAPT (0.43) MAPTHSD17B10ALDH1A1POLBHPGD
SCHEMBL11944203 0.84 CCND1 (0.35) MAPTCNR2GPR119PKMNAMPT
SCHEMBL11944270 0.83 HPGD (0.44) MAPTHSD17B10ALDH1A1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA KDM4E 1548/4885GLA 86/4885MAPT 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback